Latest & greatest articles for prednisone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prednisone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prednisone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prednisone

21. Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma 26802176 2016 03 04 2016 07 27 2016 03 04 1528-0020 127 9 2016 Mar 03 Blood Blood Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. 1109-16 10.1182/blood-2015-11-679415 The combination of melphalan, prednisone, and thalidomide (MPT) is considered standard therapy for newly diagnosed patients with multiple myeloma (...) who are ineligible for stem cell transplantation. Long-term treatment with thalidomide is hampered by neurotoxicity. Melphalan, prednisone, and lenalidomide, followed by lenalidomide maintenance therapy, showed promising results without severe neuropathy emerging. We randomly assigned 668 patients between nine 4-week cycles of MPT followed by thalidomide maintenance until disease progression or unacceptable toxicity (MPT-T) and the same MP regimen with thalidomide being replaced by lenalidomide

EvidenceUpdates2016

22. Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL 26232170 2015 10 16 2016 01 14 2017 02 20 1528-0020 126 16 2015 Oct 15 Blood Blood Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL. 1893-901 10.1182/blood-2015-03-632430 This phase 2 study evaluated whether substituting bortezomib for vincristine in frontline rituximab plus (...) cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy could improve efficacy in non-germinal center B-cell-like diffuse large B-cell lymphoma (non-GCB DLBCL), centrally confirmed by immunohistochemistry (Hans method). In total, 164 patients were randomized 1:1 to receive six 21-day cycles of rituximab 375 mg/m(2), cyclophosphamide 750 mg/m(2), and doxorubicin 50 mg/m(2), all IV day 1, prednisone 100 mg/m(2) orally days 1-5, plus either bortezomib 1.3 mg/m(2) IV days 1, 4, 8, 11 (rituximab

EvidenceUpdates2016 Full Text: Link to full Text with Trip Pro

23. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial.

Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. BACKGROUND: Clinical trials yielded conflicting data about the benefit of adding systemic corticosteroids for treatment of community-acquired pneumonia. We assessed whether short-term corticosteroid treatment reduces time to clinical stability in patients admitted to hospital for community-acquired pneumonia. METHODS: In this double-blind, multicentre (...) , randomised, placebo-controlled trial, we recruited patients aged 18 years or older with community-acquired pneumonia from seven tertiary care hospitals in Switzerland within 24 h of presentation. Patients were randomly assigned (1:1 ratio) to receive either prednisone 50 mg daily for 7 days or placebo. The computer-generated randomisation was done with variable block sizes of four to six and stratified by study centre. The primary endpoint was time to clinical stability defined as time (days) until

Lancet2015

24. Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations?

Is Dexamethasone as Effective as Prednisone or Prednisolone in the Management of Pediatric Asthma Exacerbations? DEFINE_ME_WA This site requires Cookies to be enabled to function. Please ensure Cookies are turned on and then re-visit the desired page.

Annals of Emergency Medicine Systematic Review Snapshots2015

25. Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer 24323035 2014 01 09 2014 03 03 2016 11 25 1527-7755 32 2 2014 Jan 10 Journal of clinical oncology : official journal of the American Society of Clinical Oncology J. Clin. Oncol. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant (...) prostate cancer. 76-82 10.1200/JCO.2012.48.5268 We evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC). Men with progressive mCRPC after docetaxel-based chemotherapy were randomly assigned 2:1 to receive sunitinib 37.5 mg/d continuously or placebo. Patients also received oral prednisone 5 mg twice daily. The primary end point was overall survival (OS); secondary end points included progression-free survival

EvidenceUpdates2014

26. Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department

Systematic review and meta-analysis: Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Dexamethasone may be a viable alternative to prednisone/prednisolone for the treatment of acute asthma exacerbation in the paediatric emergency department Article Text

Evidence-Based Medicine (Requires free registration)2014

27. Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re

Long-term clinical follow-up of the multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Re 23492671 2013 06 17 2014 01 23 2015 11 19 1522-9645 34 23 2013 Jun European heart journal Eur. Heart J. Long-term clinical follow-up of the multicentre, randomized study to test immunosuppressive therapy with oral prednisone for the prevention (...) of restenosis after percutaneous coronary interventions: Cortisone plus BMS or DES veRsus BMS alone to EliminAte Restenosis (CEREA-DES). 1740-8 10.1093/eurheartj/eht079 To analyse the clinical outcome at 4 years in patients with coronary artery disease treated with bare metal stents (BMS) vs. BMS and oral prednisone, or drug-eluting stents (DES), all assuming similar adjunctive medical treatment. Five Italian hospitals enrolled 375 non-diabetic, ischaemic patients without contraindications to dual anti

EvidenceUpdates2013

28. Azathioprine with prednisone for polymyositis. A controlled, clinical trial.

Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Azathioprine with prednisone for ... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 1980 ) Volume: 92 , Issue: 3 , Pages: 365-369 PubMed: Available from or Find this paper at: Abstract A controlled, prospective, double-blind, therapeutic trial of azathioprine was conducted in the initial therapy of polymyositis (...) . Sixteen patients received 60 mg prednisone per day plus either azathioprine (2 mg/kg of body weight per day) or placebo for a period of 3 months. Creatine phosphokinase (CPK) levels fell to normal slightly sooner in the placebo group, but not significantly so. The azathioprine group did not become significantly stronger (P = 0.58) and did not manifest significantly greater improvement of histopathologic features of muscle (P = 0.80) than the placebo group. Initial CPK elevations were significantly

Annals of Internal Medicine2013

29. The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients With Bell?s Palsy: A Systematic Review

The Efficacy of Prednisone Versus Antivirals in the Complete Recovery of Patients With Bell?s Palsy: A Systematic Review "The Efficacy of Prednisone Versus Antivirals in the Complete Recovery " by Robin Tyner < > > > > > Title Author Date of Award Summer 8-10-2013 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Bell’s palsy is an idiopathic condition, caused by inflammatory injury to the facial nerve, resulting (...) viral etiology. Does the use of antivirals alone or in conjunction with steroids substantially increase the overall recovery in patients with Bell’s palsy? Methods: An exhaustive search was conducted using Medline-OVID, CINAHL-EBSCOhost, EBMR Multifile, and Web of Science using the keywords: Bell’s palsy, antiviral agents and prednisone or prednisolone. The NIH clinical trials site revealed no on-going or registered trials comparing the treatment of steroids and antivirals in patients with Bell’s

Pacific University EBM Capstone Project2013

30. Bortezomib (Velcade) - in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma

Bortezomib (Velcade) - in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma

Scottish Medicines Consortium2012

31. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised tri 23142059 2012 11 27 2013 02 04 2016 11 25 1474-5488 13 12 2012 Dec The Lancet. Oncology Lancet Oncol. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients (...) collected as part of the randomised, phase 3 COU-AA-301 trial of abiraterone acetate plus prednisone versus placebo plus prednisone in patients with metastatic castration-resistant prostate cancer after docetaxel chemotherapy. The COU-AA-301 trial enrolled patients with metastatic castration-resistant prostate cancer in whom one or two lines of chemotherapy (one docetaxel based) had been unsuccessful and who had Eastern Cooperative Oncology Group performance statuses of 2 or less. Pain intensity

EvidenceUpdates2012

32. Abiraterone (Zytiga) - with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC)

Abiraterone (Zytiga) - with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC)

Scottish Medicines Consortium2012

33. Long-Term Kidney Allograft Function and Survival in Prednisone-Free Regimens: Tacrolimus/Mycophenolate Mofetil versus Tacrolimus/Sirolimus

Long-Term Kidney Allograft Function and Survival in Prednisone-Free Regimens: Tacrolimus/Mycophenolate Mofetil versus Tacrolimus/Sirolimus 22282478 2012 03 08 2012 07 03 2017 02 20 1555-905X 7 3 2012 Mar Clinical journal of the American Society of Nephrology : CJASN Clin J Am Soc Nephrol Long-term kidney allograft function and survival in prednisone-free regimens: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. 504-12 10.2215/CJN.06940711 The optimal maintenance immunosuppressive (...) regimen to improve long-term renal allograft function and graft survival is yet to be determined. This observational study prospectively compared tacrolimus/sirolimus with tacrolimus/mycophenolate mofetil in renal transplant recipients using a prednisone-free regimen with over 8.5 years of follow-up. Patients received methylprednisonlone and anti-IL2 receptor antagonist (Basiliximab) induction and were blindly randomized to either the tacrolimus/mycophenolate mofetil (n=45) or tacrolimus/sirolimus (n

EvidenceUpdates2012 Full Text: Link to full Text with Trip Pro

34. Abiraterone (Zytiga) - with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Abiraterone (Zytiga) - with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer (mCRPC)

Scottish Medicines Consortium2012

35. Prednisone MR (Lodotra) - treatment of moderate to severe, active rheumatoid arthritis in adults

Prednisone MR (Lodotra) - treatment of moderate to severe, active rheumatoid arthritis in adults Published 13 February, 2012 Statement of Advice prednisone (Lodotra®) 1 mg, 2 mg and 5 mg modified-release tablets (No: 771/12) Napp Pharmaceuticals 13 January 2012 ADVICE: in the absence of a submission from the holder of the marketing authorisation prednisone (Lodotra®) is not recommended for use within NHS Scotland. Indication under review: treatment of moderate to severe, active rheumatoid

Scottish Medicines Consortium2012

36. Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids in the Treatment of Duchenne Muscular Dystrophy

Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids in the Treatment of Duchenne Muscular Dystrophy "Deflazacort Versus Prednisone: A Systematic Comparison of two Steroids" by Jaime L. Ulrich < > > > > > Title Author Date of Award Summer 8-11-2012 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Robert P. Rosenow, Pharm.D., O.D. Second Advisor Annjanette Sommers PA-C, MS Rights . Abstract Background: Duchenne muscular (...) dystrophy (DMD) is a genetic disorder in males resulting in muscle weakness leading to loss of ambulation and progression to death by pulmonary and cardiac dysfunction. It has been documented both steroids deflazacort and prednisone delay muscle degeneration but not many studies outline the differences between the two including side effect profiles. Deflazacort is not yet available in the US. This systematic review compiles recent data to compare deflazacort to prednisone in the treatment of DMD boys

Pacific University EBM Capstone Project2012

37. Rayos (prednisone) delayed release tablet

Rayos (prednisone) delayed release tablet Drug Approval Package: Rayos (prednisone) NDA #202020 Drug Approval Package U.S. Food & Drug Administration Enter Search terms Drug Approval Package - Rayos (prednisone) delayed release tablet 1 mg, 2 mg, 5 mg Company: Horizon Pharma, Inc. Application No.: 202020 Approval Date: 07/26/2012 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2012

38. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. 22607134 2012 05 24 2012 05 31 2016 12 15 1533-4406 366 21 2012 May 24 The New England journal of medicine N. Engl. J. Med. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. 1968-77 10.1056/NEJMoa1113354 A combination of prednisone, azathioprine, and N-acetylcysteine (NAC) has been widely used as a treatment for idiopathic pulmonary fibrosis. The safety and efficacy of this three-drug regimen is unknown (...) . In this randomized, double-blind, placebo-controlled trial, we assigned patients with idiopathic pulmonary fibrosis who had mild-to-moderate lung-function impairment to one of three groups -- receiving a combination of prednisone, azathioprine, and NAC (combination therapy), NAC alone, or placebo -- in a 1:1:1 ratio. The primary outcome was the change in longitudinal measurements of forced vital capacity during a 60-week treatment period. When approximately 50% of data had been collected (with 77 patients

NEJM2012 Full Text: Link to full Text with Trip Pro

39. Cabazitaxel (Jevtana) - In combination with prednisone or prednisolone, cabazitaxel is licensed for the treatment of patients with hormone refractory metastatic prostate cancer

Cabazitaxel (Jevtana) - In combination with prednisone or prednisolone, cabazitaxel is licensed for the treatment of patients with hormone refractory metastatic prostate cancer

Scottish Medicines Consortium2011

40. Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy 21753160 2011 08 03 2011 09 30 2016 12 15 1526-632X 77 5 2011 Aug 02 Neurology Neurology Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy. 444-52 10.1212/WNL.0b013e318227b164 To perform a double-blind, randomized study comparing efficacy and safety of daily and weekend prednisone in boys with Duchenne muscular dystrophy (DMD). A total of 64 boys with DMD who were (...) between 4 and 10 years of age were randomized at 1 of 12 centers of the Cooperative International Neuromuscular Research Group. Efficacy and safety of 2 prednisone schedules (daily 0.75 mg/kg/day and weekend 10 mg/kg/wk) were evaluated over 12 months. Equivalence was met for weekend and daily dosing of prednisone for the primary outcomes of quantitative muscle testing (QMT) arm score and QMT leg score. Secondary strength scores for QMT elbow flexors also showed equivalence between the 2 treatment

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro